Mark Ian Munro Noble*

Professor of Cardiovascular Medicine (honorary, visiting unpaid volunteer), Department of Medicine and Therapeutics, University of Aberdeen, Forestester Hill, Aberdeen, Scotland

*Corresponding Author: Ogbonna Onyemaechi John, Department of Pharmacology, Faculty of Basic Medical Sciences, University of Calabar, Calabar, Cross River State, Nigeria.

Received: June 25, 2018; Published: July 11, 2018

Citation: OMark Ian Munro Noble. “Incorrect Anti-coagulant Treatmen”. Acta Scientific Pharmaceutical Sciences 2.8 (2018).

Abstract

  Rivaroxaban, sold under the trade name Xarelto, is heavily promoted as an effective alternative to warfarin to reduce the risk of life-threatening blood clots. However, its potential side effects include death, bleeding into the brain and other internal organs and tissues. It is concerning that this new and heavily promoted drug is being rapidly and widely used when there are still unforeseen and serious side effects. The fundamental error is the use of single doses not normalised for body mass, and lack of monitoring tests.

Keywords: Anti-Coagulant Treatment ; Rivaroxaban ; Warfarin

Copyright: © 2018 Mark Ian Munro Noble. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.